收费全文 | 69436篇 |
免费 | 5457篇 |
国内免费 | 334篇 |
医药卫生 | 75227篇 |
2023年 | 292篇 |
2021年 | 1204篇 |
2020年 | 782篇 |
2019年 | 1106篇 |
2018年 | 1345篇 |
2017年 | 935篇 |
2016年 | 1077篇 |
2015年 | 1239篇 |
2014年 | 1923篇 |
2013年 | 3019篇 |
2012年 | 4084篇 |
2011年 | 4432篇 |
2010年 | 2531篇 |
2009年 | 2337篇 |
2008年 | 4324篇 |
2007年 | 4544篇 |
2006年 | 4355篇 |
2005年 | 4412篇 |
2004年 | 4126篇 |
2003年 | 3700篇 |
2002年 | 3628篇 |
2001年 | 964篇 |
2000年 | 853篇 |
1999年 | 926篇 |
1998年 | 833篇 |
1997年 | 672篇 |
1996年 | 459篇 |
1995年 | 535篇 |
1994年 | 530篇 |
1993年 | 476篇 |
1992年 | 702篇 |
1991年 | 680篇 |
1990年 | 587篇 |
1989年 | 605篇 |
1988年 | 533篇 |
1987年 | 510篇 |
1986年 | 492篇 |
1985年 | 558篇 |
1984年 | 492篇 |
1983年 | 486篇 |
1982年 | 568篇 |
1981年 | 486篇 |
1980年 | 547篇 |
1979年 | 378篇 |
1978年 | 370篇 |
1977年 | 375篇 |
1976年 | 327篇 |
1975年 | 349篇 |
1974年 | 307篇 |
1973年 | 282篇 |
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献